Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

dc.contributor.authorZelenetz, Andrew D.
dc.contributor.authorBarrientos, Jacqueline C.
dc.contributor.authorBrown, Jennifer R.
dc.contributor.authorCoiffier, Bertrand
dc.contributor.authorDelgado, Julio
dc.contributor.authorEgyed, Miklós
dc.contributor.authorGhia, Paolo
dc.contributor.authorIllés, Árpád
dc.contributor.authorJurczak, Wojciech
dc.contributor.authorMurlton, Paula
dc.contributor.authorMontillo, Marco
dc.contributor.authorMorschhauser, Franck
dc.contributor.authorPristupa, Alexander S.
dc.contributor.authorRobak, Tadeusz
dc.contributor.authorSharman, Jeff P.
dc.contributor.authorSimpson, David
dc.contributor.authorSmolej, Lukás
dc.contributor.authorTausch, Eugen
dc.contributor.authorAdewoye, Adeboye H.
dc.contributor.authorDreiling, Lyndah K.
dc.contributor.authorKim, Yeonhee
dc.contributor.authorStilgenbaur, Stephan
dc.contributor.authorHillmen, Peter
dc.date.accessioned2017-08-02T11:15:19Z
dc.date.available2017-08-02T11:15:19Z
dc.date.issued2017
dc.date.oa2018-03-29
dc.date.pasync2018-05-17T00:30:23Z
dc.date.updated2018-05-17T00:30:23Z
dc.description.correctorKA
dc.identifier.citationLancet Oncology. - 18 (2017), p. 297-311. -Lancet Oncol. - 1470-2045
dc.identifier.issn1470-2045
dc.identifier.opachttp://webpac.lib.unideb.hu:8082/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM070024
dc.identifier.originalhttps://www.sciencedirect.com/science/article/pii/S1470204516306714?via%3Dihub
dc.identifier.urihttp://hdl.handle.net/2437/242826
dc.languageeng
dc.rights.accessopen access pre-print és post-print
dc.rights.ownerElsevier
dc.subject.mabOrvostudományok
dc.subject.mabKlinikai orvostudományok
dc.titleIdelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
dc.typefolyóiratcikk
Fájlok
Eredeti köteg (ORIGINAL bundle)
Megjelenítve 1 - 2 (Összesen 2)
Nem elérhető
Név:
FILE_UP_0_Idelalisib or placebo in combination.pdf
Méret:
587 KB
Formátum:
Adobe Portable Document Format
Leírás:
Kiadói változat – nem hozzáférhető
Nem elérhető
Név:
Idelalisib.pdf
Méret:
881.39 KB
Formátum:
Adobe Portable Document Format
Leírás:
pre-print